NCT02342548 is a Phase 2 clinical trial of 20 mg BID of PF-02545920 in Huntington's Disease, sponsored by Pfizer.

Who is sponsoring NCT02342548?

NCT02342548 is sponsored by Pfizer.

What drugs are being tested in NCT02342548?

Interventions in NCT02342548: 20 mg BID of PF-02545920.

What condition does NCT02342548 study?

NCT02342548 studies Huntington's Disease.

Is NCT02342548 still recruiting?

NCT02342548 is currently terminated. Last updated 23 April 2018.

Are results published for NCT02342548?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2018-04-23 · How we verify

NCT02342548

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

Terminated Phase 2 Results posted Last updated 23 April 2018

What this trial tests

Phase 2 trial testing 20 mg BID of PF-02545920 in Huntington's Disease in 188 participants. Terminated before completion.

Timeline

25 February 2015

Primary endpoint
6 February 2017

6 February 2017

Quick facts

Lead sponsor	Pfizer
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	188
Start date	25 February 2015
Primary completion	6 February 2017
Estimated completion	6 February 2017
Sites	50 locations across United Kingdom, Germany, Poland, Canada, United States

Drugs / interventions tested

20 mg BID of PF-02545920 — full drug profile →

Conditions studied

Huntington's Disease — all drugs for Huntington's Disease →

Sponsor

Pfizer — full company profile →

Who can join

Adults 30 to 66, any sex, with Huntington's Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Treatment-Emergent Adverse Events and Serious Adverse Events Primary · 1 year

An adverse event (AE) was any untoward medical occurrence in a clinical investigation participant administered a product or medical device, regardless of its causal relationship with study treatment. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; was life-threatening (immediate risk of death); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs are events between first dose of study treatment and up to 28 calendar days afte

AEs

Group	Value	95% CI
20 mg PF-02545920	39
5 mg PF-02545920 Titration up to 20 mg	63
Placebo and Titration up to 20 mg PF-02545920	62

SAEs

Group	Value	95% CI
20 mg PF-02545920	7
5 mg PF-02545920 Titration up to 20 mg	9
Placebo and Titration up to 20 mg PF-02545920	5

Number of Participants With Laboratory Test Abnormalities (Without Regard to Baseline Abnormality) Primary · 1 year

The laboratory test included: hematology (hemoglobin, hematocrit, red blood cell count, platelet count, white blood cell count, absolute total neutrophils, eosinophils, monocytes, basophils, and lymphocytes), chemistry (blood urea nitrogen/urea, creatinine, glucose, glycosylated hemoglobin \[diabetics only\], calcium, phosphorus, magnesium, creatine kinase, sodium, potassium, chloride, total carbon dioxide, aspartate aminotransferase, alanine aminotransferase, lactate dehydrogenase, total bilirubin, alkaline phosphatase, uric acid, albumin, total protein), urinalysis (color, appearance, specif

Group	Value	95% CI
20 mg PF-02545920	19
5 mg PF-02545920 Titration up to 20 mg	27
Placebo and Titration up to 20 mg PF-02545920	28

Number of Participants With Vital Signs Data Meeting Categorical Summarization Criteria Primary · 1 year

Number of participants with vital signs data meeting the following criteria is presented: (1) supine systolic blood pressure (SBP) \<90 millimeters of mercury (mmHg); (2) standing SBP \<90 mmHg; (3) supine diastolic blood pressure (DBP) \<50 mmHg; (4) standing DBP \<50 mmHg; (5) supine pulse rate \<40 beats per minute (bpm); (6) supine pulse rate \>120 bpm; (7) standing pulse rate \<40 bpm; (8) standing pulse rate \>140 bpm; (9) maximum increase from baseline in supine SBP \>= 30 mmHg; (10) maximum increase from baseline in standing SBP \>= 30 mmHg; (11) maximum increase from baseline in supin

Supine SBP <90 mmHg

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Standing SBP <90 mmHg

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	1
Placebo and Titration up to 20 mg PF-02545920	0

Supine DBP <50 mmHg

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	1
Placebo and Titration up to 20 mg PF-02545920	0

Standing DBP <50 mmHg

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	1
Placebo and Titration up to 20 mg PF-02545920	0

Supine pulse rate <40 bpm

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Supine pulse rate >120 bpm

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Standing pulse rate <40 bpm

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Standing pulse rate >140 bpm

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Number of Participants With Electrocardiogram (ECG) Data Meeting Categorical Summarization Criteria Primary · 1 year

Maximum absolute values and increases from baseline were summarized for PR interval (interval between the start of the ECG P wave and the start of the QRS complex corresponding to the time between the onset of the atrial depolarization and onset of ventricular depolarization), QRS complex (time from Q wave to the end of the S wave corresponding to ventricular depolarization), and QTcF interval (time from ECG Q wave to the end of T wave corresponding to electrical systole, corrected for heart rate using Fridericia's formula). Number of participants with ECG data meeting the following criteria i

PR interval >=300 msec

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

QRS complex >=140 msec

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

QTcF interval: 450 to <480 msec

Group	Value	95% CI
20 mg PF-02545920	2
5 mg PF-02545920 Titration up to 20 mg	2
Placebo and Titration up to 20 mg PF-02545920	2

QTcF interval: 480 to <500 msec

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	1

QTcF interval >=500 msec

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

PR interval increase from baseline >=25/50 percent

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

QRS complex increase from baseline >=50 percent

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

QTcF increase from baseline: 30 to <60 msec

Group	Value	95% CI
20 mg PF-02545920	3
5 mg PF-02545920 Titration up to 20 mg	5
Placebo and Titration up to 20 mg PF-02545920	4

Number of Participants With Abnormal White Blood Cell Count and Absolute Neutrophil Count (Without Regard to Baseline Abnormality) Primary · 1 year

Number of participants with white blood cell (WBC) count and absolute neutrophil count (ANC) meeting the following criteria is presented: (1) WBC count \<0.6 \*the lower limit of normal (LLN); (2) WBC count \>1.5 times the upper limit of normal (ULN); (3) ANC \<0.8\*LLN; and (4) ANC \>1.2\*ULN.

WBC < 0.6*LLN

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

WBC > 1.5*ULN

Group	Value	95% CI
20 mg PF-02545920	1
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	1

ANC < 0.8*LLN

Group	Value	95% CI
20 mg PF-02545920	1
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

ANC > 1.2*ULN

Group	Value	95% CI
20 mg PF-02545920	3
5 mg PF-02545920 Titration up to 20 mg	4
Placebo and Titration up to 20 mg PF-02545920	7

Number of Participants With Laboratory Test Abnormalities (Normal Baseline) Primary · 1 year

Group	Value	95% CI
20 mg PF-02545920	13
5 mg PF-02545920 Titration up to 20 mg	22
Placebo and Titration up to 20 mg PF-02545920	23

Number of Participants With Adverse Events Related to Extrapyramidal Symptoms by Severity Primary · 1 year

Adverse events related to extrapyramidal symptoms included dystonia, akathisia, tardive dyskinesia). Severity was assessed by the investigator. Mild means the AE didn't interfere with the participant's usual function. Moderate means the AE interfered to some extent the participant's usual function. Severe means the AE interfered significantly with the participant's usual function.

Mild dystonia

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	1
Placebo and Titration up to 20 mg PF-02545920	0

Moderate dystonia

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	1
Placebo and Titration up to 20 mg PF-02545920	1

Severe dystonia

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Mild akathisia

Group	Value	95% CI
20 mg PF-02545920	1
5 mg PF-02545920 Titration up to 20 mg	1
Placebo and Titration up to 20 mg PF-02545920	0

Moderate akathisia

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	1
Placebo and Titration up to 20 mg PF-02545920	3

Severe akathisia

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	1

Mild dyskinesia

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	2
Placebo and Titration up to 20 mg PF-02545920	4

Moderate dyskinesia

Group	Value	95% CI
20 mg PF-02545920	1
5 mg PF-02545920 Titration up to 20 mg	1
Placebo and Titration up to 20 mg PF-02545920	2

Number of Participants in Each Columbia Classification Algorithm of Suicide Assessment (C-CASA) Category Primary · Baseline (Day 1), Weeks 2 and 4, Months 3, 6, 9 and 12, follow-up visit (7-14 days after the last dose of Month 12)

Columbia Suicide Severity Rating Scale (C-SSRS) was an interview-based rating scale to systematically assess suicidal ideation and suicidal behavior, and was used in this study. C-SSRS responses were mapped onto the Columbia Classification Algorithm of Suicide Assessment (C-CASA). Number of participants with any of the following behaviors occurring since last visit was summarized: completed suicide; suicide attempt; preparatory acts towards suicide; suicidal ideation; self-injurious behavior (no suicidal intent).

Day 1: completed suicide

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Day 1: suicide attempt

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Day 1: preparatory acts towards suicide

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Day 1: suicidal ideation

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	1
Placebo and Titration up to 20 mg PF-02545920	1

Day 1: self-injurious behavior

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Week 2: completed suicide

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Week 2: suicide attempt

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Week 2: preparatory acts towards suicide

Group	Value	95% CI
20 mg PF-02545920	0
5 mg PF-02545920 Titration up to 20 mg	0
Placebo and Titration up to 20 mg PF-02545920	0

Change From Baseline in Unified Huntington's Disease Rating Scale (UHDRS) Total Motor Score Secondary · Baseline (Day 1), Month 6, and Month 12

The UHDRS is a clinical rating scale developed to provide a uniform assessment of the clinical features and course of Huntington's disease (HD). The components of the full UHDRS assess motor function, cognition, behavior and functional abilities. Total Motor Score (TMS) assesses motor features of HD with standardized ratings of oculomotor function, dysarthria, chorea, dystonia, gait, and postural ability. The total motor impairment scores was the sum of all the individual 31 motor sub-items (each rated from 0 to 4), with higher scores indicating more severe motor impairment than lower scores.

Month 6

Group	Value	95% CI
20 mg PF-02545920	2.4	± 7.21
5 mg PF-02545920 Titration up to 20 mg	3.5	± 7.61
Placebo and Titration up to 20 mg PF-02545920	0.7	± 7.43

Month 12

Group	Value	95% CI
20 mg PF-02545920	4.9	± 10.17
5 mg PF-02545920 Titration up to 20 mg	3.3	± 6.71
Placebo and Titration up to 20 mg PF-02545920	0.6	± 8.24

Change From Baseline in Unified Huntington's Disease Rating Scale (UHDRS) Total Maximum Chorea (TMC) Score Secondary · Baseline (Day 1), Month 6, and Month 12

The UHDRS is a clinical rating scale developed to provide a uniform assessment of the clinical features and course of Huntington's disease (HD). The components of the full UHDRS assess motor function, cognition, behavior and functional abilities. Total Maximum Chorea (TMC) is a subset of the TMS assessment, and composed of the scoring of 7 chorea assessments (face, orobuccolingual, trunk, right and left upper extremities, right and left lower extremities). Each assessment is rated from 0 to 4 (absent to prolonged). TMC is obtained by adding up each of the separate scores, leading to max score

Month 6

Group	Value	95% CI
20 mg PF-02545920	0.1	± 3.12
5 mg PF-02545920 Titration up to 20 mg	1.3	± 3.97
Placebo and Titration up to 20 mg PF-02545920	1.4	± 4.14

Month 12

Group	Value	95% CI
20 mg PF-02545920	0.1	± 4.92
5 mg PF-02545920 Titration up to 20 mg	0.8	± 1.64
Placebo and Titration up to 20 mg PF-02545920	0.7	± 3.51

Absolute Value in Clinical Global Impression of Improvement (CGI-I) Score Secondary · Month 6 and Month 12

The Clinical Global Impression of Improvement (CGI-I) is a global measure of improvement or change based on the clinician's assessment of all available clinical data obtained from interviewing the participant. The CGI-I consists of a single 7-point rating of total improvement or change from baseline severity, regardless of whether or not the change is due entirely to drug treatment. Raters select 1 response based on the following question, "Compared to your participant's condition at the beginning of treatment, how much has he/she changed?" Scores are: 1: Very much improved; 2: Much improved;

Month 6

Group	Value	95% CI
20 mg PF-02545920	3.9	± 1.04
5 mg PF-02545920 Titration up to 20 mg	4.2	± 1.03
Placebo and Titration up to 20 mg PF-02545920	3.7	± 1.19

Month 12

Group	Value	95% CI
20 mg PF-02545920	3.5	± 1.30
5 mg PF-02545920 Titration up to 20 mg	4.6	± 1.13
Placebo and Titration up to 20 mg PF-02545920	4.0	± 1.21

Adverse events — posted to ClinicalTrials.gov

Time frame: 1 year. Reporting threshold: 5%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

20 mg PF-02545920

Serious: 7/51 (14%)

Deaths: 0/51

5 mg PF-02545920 Titration up to 20 mg

Serious: 9/71 (13%)

Deaths: 0/71

Placebo and Titration up to 20 mg PF-02545920

Serious: 5/66 (8%)

Deaths: 0/66

Serious adverse events (24 terms)

Reaction	System	20 mg PF-02545920	5 mg PF-02545920 Titration…	Placebo and Titration up t…
Hyperkinesia	Nervous system disorders	—	—	—
Huntington's disease	Congenital, familial and genetic disorders	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—
Pancreatitis	Gastrointestinal disorders	—	—	—
Complication associated with device	General disorders	—	—	—
Cholelithiasis	Hepatobiliary disorders	—	—	—
Cervical vertebral fracture	Injury, poisoning and procedural complications	—	—	—
Fall	Injury, poisoning and procedural complications	—	—	—
Blood creatine phosphokinase increased	Investigations	—	—	—
Weight decreased	Investigations	—	—	—
Dehydration	Metabolism and nutrition disorders	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—
Intervertebral disc protrusion	Musculoskeletal and connective tissue disorders	—	—	—
Osteoarthritis	Musculoskeletal and connective tissue disorders	—	—	—
Chorea	Nervous system disorders	—	—	—
Syncope	Nervous system disorders	—	—	—
Transient ischaemic attack	Nervous system disorders	—	—	—
Agitation	Psychiatric disorders	—	—	—
Depression	Psychiatric disorders	—	—	—
Panic attack	Psychiatric disorders	—	—	—
Suicide attempt	Psychiatric disorders	—	—	—
Urinary tract disorder	Renal and urinary disorders	—	—	—
Prostatomegaly	Reproductive system and breast disorders	—	—	—
Cough	Respiratory, thoracic and mediastinal disorders	—	—	—

Other adverse events (23 terms — click to expand)

Reaction	System	20 mg PF-02545920	5 mg PF-02545920 Titration…	Placebo and Titration up t…
Fall	Injury, poisoning and procedural complications	—	—	—
Chorea	Nervous system disorders	—	—	—
Weight decreased	Investigations	—	—	—
Nausea	Gastrointestinal disorders	—	—	—
Fatigue	General disorders	—	—	—
Dizziness	Nervous system disorders	—	—	—
Somnolence	Nervous system disorders	—	—	—
Insomnia	Psychiatric disorders	—	—	—
Viral upper respiratory tract infection	Infections and infestations	—	—	—
Hyperkinesia	Nervous system disorders	—	—	—
Anxiety	Psychiatric disorders	—	—	—
Diarrhoea	Gastrointestinal disorders	—	—	—
Back pain	Musculoskeletal and connective tissue disorders	—	—	—
Dyskinesia	Nervous system disorders	—	—	—
Vomiting	Gastrointestinal disorders	—	—	—
Headache	Nervous system disorders	—	—	—
Sedation	Nervous system disorders	—	—	—
Depression	Psychiatric disorders	—	—	—
Restlessness	Psychiatric disorders	—	—	—
Dysphagia	Gastrointestinal disorders	—	—	—
Akathisia	Nervous system disorders	—	—	—
Muscle spasms	Musculoskeletal and connective tissue disorders	—	—	—
Sleep disorder	Psychiatric disorders	—	—	—

Most-reported serious reactions: Hyperkinesia, Huntington's disease, Dysphagia, Pancreatitis, Complication associated with device, Cholelithiasis, Cervical vertebral fracture, Fall.

Data from ClinicalTrials.gov NCT02342548 adverse events section.

Sponsor's own description

This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920. Secondary endpoints will be the change from baseline in the Total Motor Score (TMS)assessment, and/ior the Total maximum Chorea (TMC) assessment of the Unified Huntington Disease Rating Scale (UHDRS) after 6 and 12 months of treatment, and Clinical Global Impression-Improvement score after 6 and 12 months of treatment. Subjects, who were assigned to the 20 mg PF-02545920 dose group in the preceding A8241021 study, will receive 20 mg PF-02545920 without any titration. All other subjects will be titrated to the 20 mg BID dose as follows: 5 mg BID for 7 days, 10 mg BID for 7 days, 15 mg BID for 7 days, then 20 mg BID for the remainder of the treatment phase. Up to 260 subjects may take part in this open label extension

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Therapeutic targeting of 3',5'-cyclic nucleotide phosphodiesterases: inhibition and beyond.
Baillie GS, Tejeda GS, Kelly MP. · · 2019 · cited 263× · PMID 31388135 · DOI 10.1038/s41573-019-0033-4
From Pathogenesis to Therapeutics: A Review of 150 Years of Huntington's Disease Research.
Jiang A, Handley RR, Lehnert K, Snell RG. · · 2023 · cited 88× · PMID 37629202 · DOI 10.3390/ijms241613021
Clinical Trials Corner: September 2017.
Rodrigues FB, Wild EJ. · · 2017 · cited 33× · PMID 28968245 · DOI 10.3233/jhd-170262
Chorea-related mutations in PDE10A result in aberrant compartmentalization and functionality of the enzyme.
Tejeda GS, Whiteley EL, Deeb TZ, Bürli RW, et al · · 2020 · cited 10× · PMID 31871190 · DOI 10.1073/pnas.1916398117
Inhibition of Phosphodiesterase 10A by MP-10 Rescues Behavioral Deficits and Normalizes Microglial Morphology and Synaptic Pruning in A Mouse Model of FOXP1 Syndrome.
Fröhlich H, Wang J, Althammer F, Schubert T, et al · · 2025 · cited 1× · PMID 40568906 · DOI 10.1002/advs.202500623

Verify or expand the search:

Other recruiting trials for Huntington's Disease

Currently open trials in the same condition.

NCT07246941 — A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease · Phase 1 · recruiting
NCT06585449 — A Study to Evaluate ALN-HTT02 in Adult Patients With Huntington's Disease · Phase 1 · recruiting
NCT02855476 — HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02342548 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 23 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02342548.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing

NCT02342548

Quick facts

Drugs / interventions tested

Conditions studied

Sponsor

Who can join

Results — posted to ClinicalTrials.gov

Adverse events — posted to ClinicalTrials.gov

Serious adverse events (24 terms)

Sponsor's own description

Publications & conference data

Related trials

Other recruiting trials for Huntington's Disease

Other Pfizer trials

Verify against primary sources